Edificio de oficinas, en Madrid

This office building was designed according to a module of 1.60 X 1.60 m, to allow for maximum flexibility in its distribution and optimum adaptation to possible future changes in the internal organisation. The structure is metallic; the external walls are in brick or glass, depending on the zone, and both the internal and external treatment have been wisely chosen in order to follow the two basic principles of functionality and comfort. This building, besides containing the main offices of the Spanish Society of Touring Cars in Madrid, also provides room for a lecture hall, an automobile exhibition hall and a department of electronic computing.<br><br>Este edificio para oficinas fue proyectado según un módulo de 1,60 x 1,60 m, de tal manera que admitiese la máxima flexibilidad en su distribución y se adaptase a todos los cambios de organización que pudieran presentarse en el futuro. La estructura es metálica; los cerramientos, de ladrillo visto y cristal, según conviene a cada zona; y en su composición y tratamientos exterior e interior se han aunado sabiamente los dos principios básicos de representatividad y confort exigidos. Además de alojar las oficinas centrales de la Sociedad Española de Automóviles de Turismo en Madrid, como elementos singulares dispone de: salón de actos, exposición de automóviles y servicio de ordenador electrónico

Streamlined computational pipeline for genetic background characterization of genetically engineered mice based on next generation sequencing data

Abstract Background Genetically engineered mice (GEM) are essential tools for understanding gene function and disease modeling. Historically, gene targeting was first done in embryonic stem cells (ESCs) derived from the 129 family of inbred strains, leading to a mixed background or congenic mice when crossed with C57BL/6 mice. Depending on the number of backcrosses and breeding strategies, genomic segments from 129-derived ESCs can be introgressed into the C57BL/6 genome, establishing a unique genetic makeup that needs characterization in order to obtain valid conclusions from experiments using GEM lines. Currently, SNP genotyping is used to detect the extent of 129-derived ESC genome introgression into C57BL/6 recipients; however, it fails to detect novel/rare variants. Results Here, we present a computational pipeline implemented in the Galaxy platform and in BASH/R script to determine genetic introgression of GEM using next generation sequencing data (NGS), such as whole genome sequencing (WGS), whole exome sequencing (WES) and RNA-Seq. The pipeline includes strategies to uncover variants linked to a targeted locus, genome-wide variant visualization, and the identification of potential modifier genes. Although these methods apply to congenic mice, they can also be used to describe variants fixed by genetic drift. As a proof of principle, we analyzed publicly available RNA-Seq data from five congenic knockout (KO) lines and our own RNA-Seq data from the Sall2 KO line. Additionally, we performed target validation using several genetics approaches. Conclusions We revealed the impact of the 129-derived ESC genome introgression on gene expression, predicted potential modifier genes, and identified potential phenotypic interference in KO lines. Our results demonstrate that our new approach is an effective method to determine genetic introgression of GEM

Biodiversidad de la sierra de La Macarena, Meta, Colombia. Parte I. Ríos Guayabero medio, bajo Losada y bajo Duda

Resultados parciales de los Convenios de Cooperación suscritos entre el Instituto de Investigación de Recursos Biológicos Alexander von Humboldt y la Corporación para el Desarrollo Sostenible del Área de Manejo Especial de La Macarena-Cormacarena (N° 18-096 y 17-194 Instituto Humboldt) y PE.GDE. 1.4.8.1.18.014 del 2018 y PE.GDE. 1.4.7.17.030 del 2017 Cormacarena), correspondientes a la “Evaluación de la biodiversidad acuática del río Guayabero, sierra de La Macarena, Meta. Fases I y II”

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial

ImportanceThe effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain.ObjectiveTo assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19.Design, Setting, and ParticipantsThe ACTIV-6 platform randomized clinical trial aims to evaluate repurposed medications for mild to moderate COVID-19. Between August 25, 2022, and January 20, 2023, a total of 1175 participants were enrolled at 103 US sites for evaluating fluvoxamine; participants were 30 years or older with confirmed SARS-CoV-2 infection and at least 2 acute COVID-19 symptoms for 7 days or less.InterventionsParticipants were randomized to receive fluvoxamine, 50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days (n = 601), or placebo (n = 607).Main Outcomes and MeasuresThe primary outcome was time to sustained recovery (defined as at least 3 consecutive days without symptoms). Secondary outcomes included time to death; time to hospitalization or death; a composite of hospitalization, urgent care visit, emergency department visit, or death; COVID-19 clinical progression scale score; and difference in mean time unwell. Follow-up occurred through day 28.ResultsAmong 1208 participants who were randomized and received the study drug, the median (IQR) age was 50 (40-60) years, 65.8% were women, 45.5% identified as Hispanic/Latino, and 76.8% reported receiving at least 2 doses of a SARS-CoV-2 vaccine. Among 589 participants who received fluvoxamine and 586 who received placebo included in the primary analysis, differences in time to sustained recovery were not observed (adjusted hazard ratio [HR], 0.99 [95% credible interval, 0.89-1.09]; P for efficacy = .40]). Additionally, unadjusted median time to sustained recovery was 10 (95% CI, 10-11) days in both the intervention and placebo groups. No deaths were reported. Thirty-five participants reported health care use events (a priori defined as death, hospitalization, or emergency department/urgent care visit): 14 in the fluvoxamine group compared with 21 in the placebo group (HR, 0.69 [95% credible interval, 0.27-1.21]; P for efficacy = .86) There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) but no deaths.Conclusions and RelevanceAmong outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of COVID-19 symptoms.Trial RegistrationClinicalTrials.gov Identifier: NCT04885530